Search

Your search keyword '"Feelders, Richard A."' showing total 851 results

Search Constraints

Start Over You searched for: Author "Feelders, Richard A." Remove constraint Author: "Feelders, Richard A."
851 results on '"Feelders, Richard A."'

Search Results

1. Reproducible radiomics through automated machine learning validated on twelve clinical applications

2. Relacorilant, a Selective Glucocorticoid Receptor Modulator in Development for the Treatment of Patients With Cushing Syndrome, Does Not Cause Prolongation of the Cardiac QT Interval

6. Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study

7. How to manage Cushing's disease after failed primary pituitary surgery.

8. PRAP study—partial versus radical adrenalectomy in hereditary pheochromocytomas.

9. PRAP study - Partial versus radical adrenalectomy for hereditary pheochromocytomas

12. Improvements in diabetes and hypertension were sustained over long-term osilodrostat treatment in patients with Cushing's disease: A pooled analysis of LINC 3 and LINC 4

13. Venous thromboembolism in Cushing syndrome: results from an EuRRECa and Endo-ERN survey

15. Epigenetic Mechanisms Modulated by Glucocorticoids With a Focus on Cushing Syndrome

16. High prevalence of venous thrombotic events in Cushing’s syndrome:data from ERCUSYN and details in relation to surgery

17. Approach to the Patient: Insulinoma

21. Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing

22. CYP11B1 variants influence skeletal maturation via alternative splicing

26. Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease

28. Relacorilant, a Selective Glucocorticoid Receptor Modulator in Development for the Treatment of Patients With Cushing Syndrome, Does Not Cause Prolongation of the Cardiac QT Interval

29. THU033 High Prevalence Of Venous Thrombotic Events In Cushing’s Syndrome: Data From ERCUSYN

31. Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial

35. Long-Term Outcomes of Submaximal Activities of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients

36. Long-term efficacy and safety of osilodrostat in patients with Cushing’s disease: results from the LINC 4 study extension

38. The Role of the IGF2 Methylation Score in Diagnosing Adrenocortical Tumors with Unclear Malignant Potential—Feasibility of Formalin-Fixed Paraffin-Embedded Tissue

40. High prevalence of venous thrombotic events in Cushing's syndrome: data from ERCUSYN and details in relation to surgery.

43. Venous thrombotic events (VTE) across ERCUSYN: details of these VTE's and do centres anticoagulate on a routine bases?

44. An Open-Label Extension Study to Evaluate the Safety of Long-term Use of Relacorilant in Patients With Endogenous Cushing Syndrome

45. Impact of Surgery or Medical Treatment with the Selective Glucocorticoid Receptor Modulator Relacorilant on Hypercoagulopathy in Patients with Cushing Syndrome

46. Pooled analysis from two osilodrostat Phase III studies in Cushing's disease (LINC 3 and LINC 4): Clinical improvements according to urinary and late-night salivary cortisol levels

49. Abstract #1403093: Absence of QT Prolongation Associated with Relacorilant, a Selective Glucocorticoid Receptor Modulator in Development for the Treatment of Cushing Syndrome

50. Supplement 1 from Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors

Catalog

Books, media, physical & digital resources